Speakers
Mondher Toumi, MSc, PhD, MD, Aix-Marseille University, Marseille, France; Frank-Ulrich Fricke, PhD, MSc, Technische Hochschule Nürnberg, Nuremberg, Germany; Keith H Tolley, BA, MPhil, MPP, Tolley Limited, Buxton, United Kingdom; Krzysztof Kloc, Clever-Access, Kraków, Poland; Claudio Jommi, MSc, Universita del Piemonte Orientale, Milan, Italy
Separate registration required.
Pharmaceutical reimbursement systems in Europe are complex, diverse, and heterogeneous, shaped by national policies, healthcare priorities, regulatory frameworks and underlying epistemological choices. This short course offers an in-depth exploration of these systems, focusing on the decision-making processes that determine whether and how new medicines are reimbursed or accessible across key European markets.
Unlike marketing authorization for pharmaceuticals (mainly regulated at the European level by EMA), pricing and reimbursement decisions in Europe are managed by individual member states. Health care services are generally covered by a single public health insurer operating under the Ministry of Health supervision. As a monopoly buyer (monopsony), this situation provides a leading position for the public health insurer to set reimbursement conditions. On the other side, pharmaceutical companies may be in a monopoly situation with a single provider or very few for the same medicinal class. Therefore, based on each country’s set of regulations, processes, and values, wide variations exist in pricing and reimbursement decisions of pharmaceuticals driven by power positions and desirability of new products. This course is essential for professionals involved in market access, health economics, regulatory affairs, and policymaking, providing the tools and knowledge needed to navigate the evolving landscape of pharmaceutical reimbursement in Europe.
Topic
Health Policy & Regulatory